Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

543 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C-reactive protein levels and outcomes after statin therapy.
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. Ridker PM, et al. Among authors: rifai n. N Engl J Med. 2005 Jan 6;352(1):20-8. doi: 10.1056/NEJMoa042378. N Engl J Med. 2005. PMID: 15635109 Free article. Clinical Trial.
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Ridker PM, et al. Among authors: rifai n. J Am Coll Cardiol. 2005 May 17;45(10):1644-8. doi: 10.1016/j.jacc.2005.02.080. Epub 2005 Apr 25. J Am Coll Cardiol. 2005. PMID: 15893181 Free article. Clinical Trial.
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E; PROVE IT-TIMI 22 Investigators. Ray KK, et al. Among authors: rifai n. J Am Coll Cardiol. 2005 Oct 18;46(8):1417-24. doi: 10.1016/j.jacc.2005.08.024. J Am Coll Cardiol. 2005. PMID: 16226164 Free article. Clinical Trial.
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators. Sabatine MS, et al. Among authors: rifai n. Circulation. 2007 Mar 27;115(12):1528-36. doi: 10.1161/CIRCULATIONAHA.106.649939. Epub 2007 Mar 19. Circulation. 2007. PMID: 17372173 Clinical Trial.
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E; Thrombolysis in Myocardial Infarction (TIMI) Study Group. Scirica BM, et al. Among authors: rifai n. Clin Chem. 2007 Oct;53(10):1800-7. doi: 10.1373/clinchem.2007.087957. Epub 2007 Aug 23. Clin Chem. 2007. PMID: 17717132 Clinical Trial.
Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.
Scirica BM, Cannon CP, Sabatine MS, Jarolim P, Sloane S, Rifai N, Braunwald E, Morrow DA; PROVE IT-TIMI 22 Investigators. Scirica BM, et al. Among authors: rifai n. Clin Chem. 2009 Feb;55(2):265-73. doi: 10.1373/clinchem.2008.117192. Epub 2008 Dec 12. Clin Chem. 2009. PMID: 19074516 Clinical Trial.
543 results